DM
8
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Causes of Delayed Presentation of MI Patients to a Tertiary Care Hospital
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive Dysfunction in Alzheimer's Disease
Lap-Band Surgery on Adolescents for Safety and Efficacy
Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM
Impact of P53 and SIRT1 in Type 2 Diabetes
Early Detection of Cognitive Dysfunction in Diabetes
Electrodiagnostic Parameters in Patients With Impaired Glucose Tolerance and Diabetes Mellitus